MIMETAS joins European consortium to help bridging ‘key knowledge gap’ in Parkinson’s research
New, more effective treatments are urgently needed for the more than one million people living with Parkinson’s in Europe today. While there are therapies available for the condition, they do not improve all symptoms, nor do they slow or prevent disease progression over time, and long-term treatment is associated with adverse side effects.
PD-MitoQUANT is an EU-funded Innovative Medicines Initiative (IMI) research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future. The project will run for 3 years, starting from 01 February 2019, receiving 4.5 million euro in funding from the EU’s Horizon 2020 programme and 2.46 million euro in-kind from European Federation of Pharmaceutical Industries and Associations (EFPIA) members and Parkinson’s UK. The project involves 14 partners from 9 countries.
MIMETAS will conduct morpho-functional in vitro studies on 3D cultures using the OrganoPlate®, as well as contribute to signature validation.
PD-MitoQUANT has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
The material presented and views expressed here reflect the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.